Nymox spikes on startling success of animal cancer study

Shares of Nymox spiked dramatically this morning, soaring 59 percent on the news that its experimental therapy for a common type of liver cancer proved highly effective in animal studies.

Typically, preclinical data would have little impact on a share price, but Nymox is investigating a new drug--NX-1207--that has been reformulated from a therapy now in late-stage trials for benign prostatic hyperplasia. Researchers say that the reformulation, given in higher dosages, produced strongly positive results for human-transplanted hepatocellular carcinoma, which is responsible for 90 percent of primary liver cancer cases. The investigators reported that tumors shrank an average of 50 percent in rodents after two injections.

Each year more than 600,000 people die from primary liver cancer. Nymox says that it is ready to start human trials.

- check out the Nymox release
- read the Dow Jones report

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.